Prospective clinical evaluation of transdermal fentanyl for the treatment of cancer pain

Clinical and Translational Oncology

Volumn 2, Issue 3, 2000, Pages 159-163

  Cerezo, Laura ^a   Marín, Alicia ^a   Zapatero, Almudena ^a   De Vidales, Carmen Martín ^a   López, Mario ^a   Pérez Torrubia, Armando ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Cancer pain; Opioid analgesics; Transdermal fentanyl

Indexed keywords

EID: 84873671818     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Díaz-Rubio E. Dolor en el paciente canceroso. Madrid: ELA Editorial Libro del Año S.L., 1996; 9-30.
2. Torres LM, Calderón E, Rey RM. Fentanilo transdérmico (Durogesic): características farmacológicas y aplicación clínica. Rev Soc Esp Dolor 1999; 6: 121-131.
3. Payne R. Experience with transdermal fentanyl in advanced cancer pain. Eur J Pain 1990; 11: 98-101.
4. Yeo W, Lam KK, Chan A, Leung T, Wu Nip S, Johnson P. Transdemal fentanyl for severe cancer-related pain. Palliat Med 1997; 11: 233-239.
5. Zech D, Grond S, Lynch J Dauer H, Stollenwerk B, Lehmann K. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 1992; 50: 293-301.
6. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996; 64: 527-534.
7. Ventafridda V, Tamburini M, Caraceni A, Conno F, Naldi F. A Validation Study of the WHO Method for Cancer Pain Relief. Cancer 1987; 59: 850-856.
8. Bloor K, Leese B, Maynard A. The costs of managing severe cancer pain and potential savings from transdermal administration. Eur J Cancer 1994; 30: 463-468.
9. Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989; 70: 928-934.
10. Portenoy R, Southam M, Gupta S, Lapin J, Layman M, Inturrisi C et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anaesthesiology 1993; 78: 36-43.
11. Grond S, Zech D, Lehmann K, Radbruch L, Breitenbach H, Hertel D. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 1997; 69: 191-198.
12. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998; 15: 168-175.
13. Korte W, Morant R. Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding. A pilot study in 20 patients. Support Care Cancer 1994; 2: 123-127.
14. Sloan P, Moulin D, Hays H. A clinical evaluation of trans - dermal therapeutic system fentanyl for the treatment of cacer pain. J Pain Symptom Manage 1998; 16: 102-111.
15. Zech D, Grond S, Lynch J, Hertel D, Lehmann K. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995; 63: 65-76.
16. Christie J, Simmonds M, Patt R. Coluzzi P, Busch M, Nordbrock E et al. Dose-titration, multicenter study of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998; 16: 3238-3245.
17. Sevarino F, Paige D, Sinatra R, Silverman D. Postoperative analgesia with parenteral opioids: does continous delivery utilizing a transdermal opioid preparation affect analgesic efficacy or patient safety? J Clin Anesth 1997; 9: 173-178.
18. Sandler A, Baxter A, Katz J, Samson B, Friedlander M, Norman P et al. A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory and pharmacokinetic effects. Anesthesiology 1994; 81: 1169-1180.
19. Payne R. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semin Oncol 1998; 25: 47-53.
20. Ahmedzai S, Brooks D. Transdermal Fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997; 13: 254-261.
21. Wong J, Chiu G, Tsao C, Chang C. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997; 35: 25-32.
22. Payne R, Mathias S, Pasta D, Wanke L, Williams R, Mahmoud R. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16: 1588-1593.